Mastering Options for Beginners: How to Profit Even in a Sideways Market
Written by: John LinDahl There are many myths about options being risky. While risk is inherent in any investment, options, when used correctly, can mitigate risk, and increase profit. Have you ever bought a stock because you thought it was going to go up, but instead it went up a little, down a little, and moved sideways? This has [...]
Is There Still Room to Buy Palantir (PLTR) After 133% Gain YTD? 3 Things to Consider
Palantir Technologies (PLTR) has been on a torrent charge through 2024 thus far, up more than 133% - and up 156% since this time last year. While the industry has a whole has boomed, this particular stock has outpaced its peers by nearly 28%. The question is, should you still buy PLTR today, or did you miss the opportunity? [...]
Chevron, ExxonMobil, and Other Energy Stocks are Climbing on Middle East Conflict: Is it Time to Buy?
It’s like clockwork. Anytime there’s tension in the Middle East it poses a threat to the world’s oil supply, and prices surge accordingly. That’s what we’re seeing this morning for energy stocks like Chevron (CVX) and ExxonMobil (XOM). These stocks are up nearly 6% and 7% respectively in the past week, and they’re up marginally today as well. This [...]
Nike Falls 6% on Dwindling Sales and Profits in Q1 With Weak Guidance for Q2: Is it Time to Sell NKE?
Nike Inc. (NKE) is down roughly 6% Wednesday morning after the company’s earnings day Tuesday left much to be desired in the eyes of investors. The company is still struggling to regain its footing, and after withdrawing its full-year guidance, it’s clear that the road ahead will continue to be rocky. Here’s how the footwear brand performed in the [...]
Stellantis Shares Fall Amidst Forecast Cuts: While it May Be Time for Investors to Sell STLA
Shares of Stellantis NV (STLA) are down 11% in the past week as the Netherlands-based automaker was forced to lower its full-year forecast as costs are climbing while production is falling. The company was originally expecting to deliver a double-digit profit percentage for the fiscal year, but now, the profit guidance has been brought down to just 5.5% to [...]
Bristol Myer Stock Gets a Bump on FDA Approval for Schizophrenia Drug: Is it Time to Buy BMY?
Late last week Bristol Myers Squibb (BMY) got a nice 8% boost after sharing news that it gained approval from the Food and Drug Administration (FDA) for its schizophrenia drug. The stock has cooled off since and is up just shy of 4% over the past week, but it has been on a serious tear over the past few [...]
